Patents by Inventor Srimoyee Ghosh

Srimoyee Ghosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
    Publication number: 20230416368
    Abstract: Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: July 18, 2023
    Publication date: December 28, 2023
    Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
  • Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 11753472
    Abstract: Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM 3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: September 12, 2023
    Assignees: Tesaro, Inc., Anaptysbio, Inc.
    Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
  • ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
    Publication number: 20220169734
    Abstract: The disclosure provides antibody agents that bind to a T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-TIM-3 antibody agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: October 27, 2021
    Publication date: June 2, 2022
    Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
  • ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF
    Publication number: 20220135670
    Abstract: The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.
    Type: Application
    Filed: April 27, 2018
    Publication date: May 5, 2022
    Inventors: Helen Toni Jun, Marilyn Kehry, Peter Bowers, David J. King, Dmitri Bobilev, Srimoyee Ghosh, Baochuan Huang, David Jenkins
  • ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
    Publication number: 20190284280
    Abstract: The disclosure provides antibody agents that bind to a T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-TIM-3 antibody agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: November 1, 2017
    Publication date: September 19, 2019
    Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
  • EZH2 INHIBITORS AND MODULATION OF REGULATORY T-CELL FUNCTION
    Publication number: 20180221362
    Abstract: Provided herein are methods of treating cancers characterized by a high frequency of one or more suppressive immune cells, comprising administering a therapeutically effective amount of an enhancer of zeste homolog 2 (EZH2) inhibitor. Also provided are combination therapies using an EZH2 inhibitor and a second agent that is an immunomodulator.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 9, 2018
    Inventors: Srimoyee Ghosh, Jose M. Lora
  • USE OF CBP/EP300 BROMODOMAIN INHIBITORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20160317632
    Abstract: The present invention relates to use of CBP/EP300 bromodomain inhibitors for the treatment of cancer.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 3, 2016
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Steven Bellon, Andrea Cochran, Alexandre Cote, Terry Crawford, Benjamin Fauber, Srimoyee Ghosh, Jean-Christophe Harmange, Georgia Hatzivassiliou, Hariharan Jayaram, Jeong Kim, Jose M. Lora, Steven Magnuson, Ira Mellman, Anthony F. Romero, Alexander M. Taylor, Vickie Tsui
  • SMALL MOLECULE SCREEN FOR INHIBITORS OF NFAT: AP-1: DNA INTERACTIONS
    Publication number: 20140294873
    Abstract: The invention provides a screening assay for selecting inhibitors of NFAT:Transcription factor interactions. The invention also provides compositions and methods for inhibiting immune response in a subject.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 2, 2014
    Applicant: Children Medical Center Corporation
    Inventors: Srimoyee Ghosh, Anjana Rao, Patrick G. Hogan